Urotensin II is raised in children with congenital heart disease

Heart

Volumn 92, Issue 7, 2006, Pages 983-984

  Simpson, C M ^a   Penny, D J ^a,b   Stocker, C F ^a   Shekerdemian, Lara S ^a,b  

^a MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

UROTENSIN II;

ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONGENITAL HEART DISEASE; CONTROLLED STUDY; HUMAN; OPEN HEART SURGERY; OXYGEN SATURATION; PEPTIDE ANALYSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; HEART DEFECTS, CONGENITAL; HUMANS; INFANT; UROTENSINS;

EID: 33745642115     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2005.074039     Document Type: Article

References (9)

1. Ames RS, Sarau HM, Chambers JK, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999;401:282-6.
2. Douglas SA, Tayara L, Ohlstein EH, et al. Congestive heart Failure and expression of myocardial urotensin II. Lancet 2002;359:1990-7.
3. Cheung BM, Leung R, Man YB, et al. Plasma concentration of urotensin I! is raised in hypertension. J Hypertens 2004;22:1341-4.
4. Richards AM, Nicholls MG, Lainchbury JG, et al. Plasma urotensin II in heart failure. Lancet 2002;360:545-6.
5. MacLean MR, Alexander D, Stirrat A, et al. Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol 2000;130:201-4.
6. Onan D, Pipolo L, Yang E, et al. Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol Endocrinol 2004;18:2344-54.
7. Khan TA, Bianchi C, Araujo EG, et al. Activation of pulmonary mitogen-activated protein kinases during cardiopulmonary bypass. J Surg Res 2003;115:56-62.
8. Johns DG, Ao Z, Naselsky D, et al. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol 2004;370:238-50.
9. Gaynor JW. The effect of modified ultrafiltration on the postoperative course in patients with congenital heart disease. Semin Thorac Cardiovasc Surg Pediatr Card Surg 2003;6:128-39.